Cargando…
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use
PURPOSE: The absence of specific treatments for COVID-19 leads to an intense global effort in the search for new therapeutic interventions and better clinical outcomes for patients. This review aimed to present a selection of accepted studies that reported the activity of antidepressant drugs belong...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360648/ https://www.ncbi.nlm.nih.gov/pubmed/35943535 http://dx.doi.org/10.1007/s00228-022-03372-5 |
_version_ | 1784764367511748608 |
---|---|
author | Foletto, Vitória Segabinazzi da Rosa, Taciéli Fagundes Serafin, Marissa Bolson Hörner, Rosmari |
author_facet | Foletto, Vitória Segabinazzi da Rosa, Taciéli Fagundes Serafin, Marissa Bolson Hörner, Rosmari |
author_sort | Foletto, Vitória Segabinazzi |
collection | PubMed |
description | PURPOSE: The absence of specific treatments for COVID-19 leads to an intense global effort in the search for new therapeutic interventions and better clinical outcomes for patients. This review aimed to present a selection of accepted studies that reported the activity of antidepressant drugs belonging to the selective serotonin receptor inhibitor (SSRI) class for treating the novel coronavirus. METHODS: A search was performed in PubMed and SciELO databases using the following search strategies: [(coronavirus) OR (COVID) OR (SARS-CoV-2) AND (antidepressant) OR (serotonin) OR (selective serotonin receptor inhibitors)]. In the end, eleven articles were included. We also covered information obtained from ClinicalTrials.gov in our research. RESULTS: Although several clinical trials are ongoing, only a few drugs have been officially approved to treat the infection. Remdesivir, an antiviral drug, despite favorable preliminary results, has restricted the use due to the risk of toxicity and methodological flaws. Antidepressant drugs were able to reduce the risk of intubation or death related to COVID-19, decrease the need for intensive medical care, and severely inhibit viral titers by up to 99%. Among the SSRIs studied so far, fluoxetine and fluvoxamine have shown to be the most promising against SARS-CoV-2. CONCLUSION: If successful, these drugs can substantially reduce hospitalization and mortality rates, as well as allow for fully outpatient treatment for mild-to-moderate infections. Thus, repositioning SSRIs can provide benefits when faced with a rapidly evolving pandemic such as COVID-19. |
format | Online Article Text |
id | pubmed-9360648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-93606482022-08-09 Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use Foletto, Vitória Segabinazzi da Rosa, Taciéli Fagundes Serafin, Marissa Bolson Hörner, Rosmari Eur J Clin Pharmacol Review PURPOSE: The absence of specific treatments for COVID-19 leads to an intense global effort in the search for new therapeutic interventions and better clinical outcomes for patients. This review aimed to present a selection of accepted studies that reported the activity of antidepressant drugs belonging to the selective serotonin receptor inhibitor (SSRI) class for treating the novel coronavirus. METHODS: A search was performed in PubMed and SciELO databases using the following search strategies: [(coronavirus) OR (COVID) OR (SARS-CoV-2) AND (antidepressant) OR (serotonin) OR (selective serotonin receptor inhibitors)]. In the end, eleven articles were included. We also covered information obtained from ClinicalTrials.gov in our research. RESULTS: Although several clinical trials are ongoing, only a few drugs have been officially approved to treat the infection. Remdesivir, an antiviral drug, despite favorable preliminary results, has restricted the use due to the risk of toxicity and methodological flaws. Antidepressant drugs were able to reduce the risk of intubation or death related to COVID-19, decrease the need for intensive medical care, and severely inhibit viral titers by up to 99%. Among the SSRIs studied so far, fluoxetine and fluvoxamine have shown to be the most promising against SARS-CoV-2. CONCLUSION: If successful, these drugs can substantially reduce hospitalization and mortality rates, as well as allow for fully outpatient treatment for mild-to-moderate infections. Thus, repositioning SSRIs can provide benefits when faced with a rapidly evolving pandemic such as COVID-19. Springer Berlin Heidelberg 2022-08-09 2022 /pmc/articles/PMC9360648/ /pubmed/35943535 http://dx.doi.org/10.1007/s00228-022-03372-5 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Foletto, Vitória Segabinazzi da Rosa, Taciéli Fagundes Serafin, Marissa Bolson Hörner, Rosmari Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use |
title | Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use |
title_full | Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use |
title_fullStr | Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use |
title_full_unstemmed | Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use |
title_short | Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use |
title_sort | selective serotonin reuptake inhibitor (ssri) antidepressants reduce covid-19 infection: prospects for use |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360648/ https://www.ncbi.nlm.nih.gov/pubmed/35943535 http://dx.doi.org/10.1007/s00228-022-03372-5 |
work_keys_str_mv | AT folettovitoriasegabinazzi selectiveserotoninreuptakeinhibitorssriantidepressantsreducecovid19infectionprospectsforuse AT darosatacielifagundes selectiveserotoninreuptakeinhibitorssriantidepressantsreducecovid19infectionprospectsforuse AT serafinmarissabolson selectiveserotoninreuptakeinhibitorssriantidepressantsreducecovid19infectionprospectsforuse AT hornerrosmari selectiveserotoninreuptakeinhibitorssriantidepressantsreducecovid19infectionprospectsforuse |